APA (7th ed.) Citation

Gilbert, L., Oaknin, A., Matulonis, U. A., Mantia-Smaldone, G. M., Lim, P. C., Castro, C. M., . . . O'Malley, D. M. (2023). Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology, 170, 241. https://doi.org/10.1016/j.ygyno.2023.01.020

Chicago Style (17th ed.) Citation

Gilbert, Lucy, et al. "Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology 170 (2023): 241. https://doi.org/10.1016/j.ygyno.2023.01.020.

MLA (9th ed.) Citation

Gilbert, Lucy, et al. "Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology, vol. 170, 2023, p. 241, https://doi.org/10.1016/j.ygyno.2023.01.020.